1. Vento, S, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. New England Journal of Medicine 1998; 338: 286–290.
2. Lednar, WM, et al. Frequency of illness associated with epidemic hepatitis A virus infections in adults. American Journal of Epidemiology 1985; 122: 226–233.
3. Forbes, A, Williams, R. Changing epidemiology and clinical aspects of hepatitis A. British Medical Bulletin 1990; 46: 303–318.
4. Keeffe, EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? American Journal of Gastroenterology 1995; 90: 201–205.
5. Franco, E, et al. Risk groups for hepatitis A virus infection. Vaccine 2003; 21: 2224–2233.
6. Steffen, R, Banos, A, deBernardis, C. Vaccination priorities. International Journal of Antimicrobial Agents 2003; 21: 175–180.
7. Frosner, GG, et al. Antibody against hepatitis A in seven European countries. I. Comparison of prevalence data in different age groups. American Journal of Epidemiology 1979; 110: 63–69.
8. Dienstag, JL, et al. Hepatitis A virus infection: new insights from seroepidemiologic studies. Journal of Infectious Diseases 1978; 137: 328–340.
9. Szmuness, W, et al. The prevalence of antibody to hepatitis A antigen in various parts of the world: a pilot study. American Journal of Epidemiology 1977; 106: 392–398.
10. Schenzle, D, Dietz, K, Frosner, GG. Antibody against hepatitis A in seven European countries. II. Statistical analysis of cross-sectional surveys. American Journal of Epidemiology 1979; 110: 70–76.
11. Jacobsen, KH, Koopman, JS. Declining hepatitis A seroprevalence: a global review and analysis. Epidemiology and Infection 2004; 132: 1005–1022.
12. Osborne, K, Weinberg, J, Miller, E. The European Sero-Epidemiology Network. Eurosurveillance 1997; 2: 29–31.
13. Nardone, A, Miller, E. Serological surveillance of rubella in Europe: European Sero-Epidemiology Network (ESEN2). Eurosurveillance 2004; 9: 5–7.
14. Desquesnes, M. International and regional standardization of immunoenzyme tests: methods, concerns and limitations [in French]. Revue Scientifique et Technique de l'Office International des Epizooties 1997; 16: 809–823.
15. Hesketh, L, et al. An evaluation of nine commercial EIA kits for the detection of measles specific IgG. Journal of Virological Methods 1997; 66: 51–59.
16. Andrews, N, et al. The European Sero-Epidemiology Network: standardizing the enzyme immunoassay results for measles, mumps and rubella. Epidemiology and Infection 2000; 125: 127–141.
17. Giammanco, A, et al. European Sero-Epidemiology Network: standardisation of the assay results for pertussis. Vaccine 2003; 22: 112–120.
18. de Ory, F, et al. European seroepidemiology network 2: Standardisation of assays for seroepidemiology of varicella zoster virus. Journal of Clinical Virology 2006; 36: 111–118.
19. von Hunolstein, C, et al. European sero-epidemiology network: standardisation of the results of diphtheria antitoxin assays. Vaccine 2000; 18: 3287–3296.
20. Tischer, A, et al. Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia. Epidemiology and Infection 2007; 135: 787–797.
21. Kafatos, G, et al. The European Sero-Epidemiology Network 2: standardization of assay results for hepatitis B virus. Journal of Viral Hepatitis 2007; 14: 260–268.
22. Wiedmann, M, et al. Evaluation of three commercial assays for the detection of hepatitis a virus. European Journal of Clinical Microbiology and Infectious Diseases 2003; 22: 129–130.
23. Shao, ZJ, et al. Detection of anti-HAV antibody with dot immunogold filtration assay. World Journal of Gastroenterology 2003; 9: 1508–1511.
24. Berger, R, Just, M, Althaus, B. Time course of hepatitis A antibody production after active, passive and active/passive immunisation: the results are highly dependent on the antibody test system used. Journal of Virological Methods 1993; 43: 287–297.
25. Coulepis, AG, et al. Detection of hepatitis A virus and antibody by solid-phase radioimmunoassay and enzyme-linked immunosorbent assay with monoclonal antibodies. Journal of Clinical Microbiology 1985; 22: 119–124.
26. Hess, G, et al. Analysis of immunoassays to detect antibodies to hepatitis A virus (anti-HAV) and anti-HAV immunoglobulin M. Journal of Virological Methods 1995; 51: 221–228.
27. Delem, AD. Comparison of modified HAVAB and ELISA for determination of vaccine-induced anti-HAV response. Biologicals 1992; 20: 289–291.
28. Robbins, DJ, et al. Detection of total antibody against hepatitis A virus by an automated microparticle enzyme immunoassay. Journal of Virological Methods 1991; 32: 255–263.
29. Safford, SE, Needleman, SB, Decker, RH. Radioimmunoassay for detection of antibody to hepatitis A virus. Results of clinical evaluation. American Journal of Clinical Pathology 1980; 74: 25–31.
30. Drucker, J, et al. Serologic response in human hepatitis A: detection of antibody by radioimmunoassay and immune adherence hemagglutination. Journal of Medical Virology 1979; 4: 51–58.
31. Sjogren, MH, et al. Immunogenicity of an inactivated hepatitis A vaccine. Annals of Internal Medicine 1991; 114: 470–471.
32. Kafatos, G, Andrews, N, Nardone, A (on behalf of the ESEN2 project). Model selection methodology for inter-laboratory standardisation of antibody titres. Vaccine 2005; 23: 5022–5027.
33. Anastassopoulou, CG, et al. Epidemiological patterns of hepatitis A and B in Athens, Greece in 2001. 9th European Programme for Intervention Epidemiology Training (EPIET)/EPIET Alumni Network (EAN) Scientific Seminar, Minorca, Spain, 14–16 October 2004. EU Designated surveillance networks/Abstract No. 5.
34. Lubin, JH, et al. Epidemiologic evaluation of measurement data in the presence of detection limits. Environmental Health Perspectives 2004; 112: 1691–1696.